Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Palo Alto Rejoicing at ABIOMED, Inc. (ABMD)’s 18% Spike

Page 1 of 2

ABIOMED, Inc. (NASDAQ:ABMD) spiked as high as 21% in Tuesday’s intraday trading to eventually close at 18% in the green at $72.48. The rise came on the heels of FDA’s pre-market approval (PMA) of Abiomed’s Impella 2.5 system, which is the world’s smallest heart pump and is designed to be used in certain high risk coronary procedures, including stenting and angioplasty. It helps to maintain a stable heart function and circulation among patients during these procedures. One hedge fund that celebrated Abiomed’s victory was William Leland Edward‘s Palo Alto Investors. The fund holds 2.46 million shares of ABIOMED, Inc. (NASDAQ:ABMD), valued at $93.63 million, according to its latest 13F filing.


The provider of breakthrough heart support technologies is up by a massive 177% over the last year. In comparison, the advanced medical equipment & technology industry is up by 30.7% and S&P 500 by 12.6% over the same time period. ABIOMED, Inc. (NASDAQ:ABMD)’s $13 million acquisition of Germany-based ECP Entwicklungsgesellschaft mbH (ECP) last year, whose lead product was a percutaneous expandable catheter pump that increases blood circulation from the heart with an external drive shaft must have proved vital in Impella’s development. Among the billionaires that we track, Israel Englander’s Millennium Management had the highest stake in ABIOMED, Inc. (NASDAQ:ABMD) with about 947,200 shares valued at $36.05 million.

William Leland founded Palo Alto Investors in 1989 along the philosophy of investing in companies for a long term horizon which entails a research intensive process for which the firm has hired 12 employees including five research professionals. The portfolios are both concentrated, with 20 to 30 holdings per fund, and tax efficient, as average holding period for investments is between one to three years. As of the end of last year, the market value of the fund’s portfolio stood at $1.7 billion, with 99% of the holdings in the healthcare sector. Among the fund’s top five health care picks were United Therapeutics Corporation (NASDAQ:UTHR), Clovis Oncology Inc (NASDAQ:CLVS) and BioMarin Pharmaceutical Inc. (NASDAQ:BMRN).

Palo Alto Investors’ focus on small cap stocks with market capitalizations of less than $3 billion falls in line with the strategy that we have developed at Insider Monkey. Our research has shown that investing in small cap picks of hedge funds is more profitable than investing in a portfolio comprised of the most popular stock picks among them, which are invariably large cap companies. Our small cap strategy, the stock picks of which we have been sharing in our newsletters since 2012, outperformed the S&P 500 ETF (SPY) by 79.4 percentage points since August 2012 through March 2015 and returned 132% during that period.

With 1.4 million shares valued at $181.69 million, United Therapeutics Corporation (NASDAQ:UTHR), represents the most valuable of Palo Alto’s holdings. The fund inched up its stake by some 8% during the fourth quarter in the company focused on  the development and commercialization of unique products to address the unmet medical needs of patients. The stock has appreciated by nearly 90.4% over the last 52 weeks. The $8.83 billion company recently received FDA’s approval for its Unituxin injection for the treatment of children with high-risk neuroblastoma, which is most common extracranial solid cancer in children and the most common cancer in infancy. Among the hedge funds that we track Matt Sirovich and Jeremy Mindich’s Scopia Capital hold the largest stake in United Therapeutics Corporation (NASDAQ:UTHR), which contains about 2.96 million shares, valued at $382.97 million as of the end of 2014.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!